Understanding the binding affinity of noscapines with protease of SARS-CoV-2 for COVID-19 using MD simulations at different temperatures
- PMID: 32362235
- PMCID: PMC7212547
- DOI: 10.1080/07391102.2020.1752310
Understanding the binding affinity of noscapines with protease of SARS-CoV-2 for COVID-19 using MD simulations at different temperatures
Abstract
The current outbreak of a novel coronavirus, named as SARS-CoV-2 causing COVID-19 occurred in 2019, is in dire need of finding potential therapeutic agents. Recently, ongoing viral epidemic due to coronavirus (SARS-CoV-2) primarily affected mainland China that now threatened to spread to populations in most countries of the world. In spite of this, there is currently no antiviral drug/ vaccine available against coronavirus infection, COVID-19. In the present study, computer-aided drug design-based screening to find out promising inhibitors against the coronavirus (SARS-CoV-2) leads to infection, COVID-19. The lead therapeutic molecule was investigated through docking and molecular dynamics simulations. In this, binding affinity of noscapines(23B)-protease of SARS-CoV-2 complex was evaluated through MD simulations at different temperatures. Our research group has established that noscapine is a chemotherapeutic agent for the treatment of drug resistant cancers; however, noscapine was also being used as anti-malarial, anti-stroke and cough-suppressant. This study suggests for the first time that noscapine exerts its antiviral effects by inhibiting viral protein synthesis.
Keywords: COVID-19; MD simulations; Protease of SARS-CoV-2; molecular docking; noscapine; screening.
Figures
















Similar articles
-
Molecular Binding Mechanism and Pharmacology Comparative Analysis of Noscapine for Repurposing against SARS-CoV-2 Protease.J Proteome Res. 2020 Nov 6;19(11):4678-4689. doi: 10.1021/acs.jproteome.0c00367. Epub 2020 Sep 4. J Proteome Res. 2020. PMID: 32786685
-
Optimization Rules for SARS-CoV-2 Mpro Antivirals: Ensemble Docking and Exploration of the Coronavirus Protease Active Site.Viruses. 2020 Aug 26;12(9):942. doi: 10.3390/v12090942. Viruses. 2020. PMID: 32859008 Free PMC article.
-
DFT and docking studies of designed conjugates of noscapines & repurposing drugs: promising inhibitors of main protease of SARS-CoV-2 and falcipan-2.J Biomol Struct Dyn. 2022 Apr;40(6):2600-2620. doi: 10.1080/07391102.2020.1841030. Epub 2020 Nov 3. J Biomol Struct Dyn. 2022. PMID: 33140690
-
Ginseng, a promising choice for SARS-COV-2: A mini review.J Ginseng Res. 2022 Mar;46(2):183-187. doi: 10.1016/j.jgr.2022.01.004. Epub 2022 Jan 22. J Ginseng Res. 2022. PMID: 35095288 Free PMC article. Review.
-
The current state of validated small molecules inhibiting SARS-CoV-2 nonstructural proteins.Turk J Biol. 2021 Aug 30;45(4):469-483. doi: 10.3906/biy-2106-42. eCollection 2021. Turk J Biol. 2021. PMID: 34803448 Free PMC article. Review.
Cited by
-
Identification of potential drug candidates to combat COVID-19: a structural study using the main protease (mpro) of SARS-CoV-2.J Biomol Struct Dyn. 2021 Oct;39(17):6649-6659. doi: 10.1080/07391102.2020.1798286. Epub 2020 Aug 3. J Biomol Struct Dyn. 2021. PMID: 32741313 Free PMC article.
-
Potential inhibitors of SARS-CoV-2 (COVID 19) proteases PLpro and Mpro/ 3CLpro: molecular docking and simulation studies of three pertinent medicinal plant natural components.Curr Res Pharmacol Drug Discov. 2021;2:100038. doi: 10.1016/j.crphar.2021.100038. Epub 2021 Jun 5. Curr Res Pharmacol Drug Discov. 2021. PMID: 34870149 Free PMC article.
-
Unveiling the Inhibitory Potentials of Peptidomimetic Azanitriles and Pyridyl Esters towards SARS-CoV-2 Main Protease: A Molecular Modelling Investigation.Molecules. 2023 Mar 14;28(6):2641. doi: 10.3390/molecules28062641. Molecules. 2023. PMID: 36985614 Free PMC article.
-
Computational Study on Potential Novel Anti-Ebola Virus Protein VP35 Natural Compounds.Biomedicines. 2021 Nov 30;9(12):1796. doi: 10.3390/biomedicines9121796. Biomedicines. 2021. PMID: 34944612 Free PMC article.
-
Promising role of Vitamin D and plant metabolites against COVID-19: Clinical trials review.Heliyon. 2023 Oct 21;9(11):e21205. doi: 10.1016/j.heliyon.2023.e21205. eCollection 2023 Nov. Heliyon. 2023. PMID: 37920525 Free PMC article. Review.
References
-
- Aaboud M., & ATLAS Collaboration. (2017). Determination of the strong coupling constant alpha s from transverse energy-energy correlations in multijet events at s = 8 TeV using the ATLAS detector. The European Physical Journal C, 77(12), 872, 1-34. doi. 10.1140/epjc/s10052-017-5442-0. - DOI - PMC - PubMed
-
- Aaboud M., ATLAS Collaboration, Aad G., Abbott B., Abdinov O., Abeloos B., Abhayasinghe D. K., Abidi S. H., AbouZeid O. S., Abraham N. L., Abramowicz H., Abreu H., Abulaiti Y., Acharya B. S., Adachi S., Adamczyk L., Adelman J., Adersberger M., Adiguzel A., … Zwalinski L. (2018). Probing the quantum interference between Singly and Doubly resonant top-quark production in pp collisions at sqrt[s] = 13 TeV with the ATLAS Detector. Physical Review Letters, 121(15), 152002. - PubMed
-
- Abbad A., Perera R. A., Anga L., Faouzi A., Minh N. N. T., Malik S. M. M. R., Iounes N., Maaroufi A., Van Kerkhove M. D., Peiris M., & Nourlil J. (2019). Middle East respiratory syndrome coronavirus (MERS-CoV) neutralising antibodies in a high-risk human population, Morocco, November 2017 to January 2018. Eurosurveillance, 24(48), 1900244 10.2807/1560-7917.ES.2019.24.48.1900244 - DOI - PMC - PubMed
-
- Adasme-Carreno F., Munoz-Gutierrez C., Caballero J., & Alzate-Morales J. H. (2014). Performance of the MM/GBSA scoring using a binding site hydrogen bond network-based frame selection: The protein kinase case. Physical Chemistry Chemical Physics, 16(27), 14047–14055. 10.1039/C4CP01378F - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous